Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Matias Eliseo Melendez has a total of 147 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • .

    by Matias Melendez

    Site-specific Excision-Dependent (SED) vectors : a novel concept in herpes simplex virus type-1-based gene transfer vectors: L'objectif de mon sujet de thèse était de développer un nouveau type de vecteur viral pour le transfert de gènes, et de faire la preuve de concept de l'efficacité de ce vecteur en culture de cellules et chez la souris. L'idée centrale est de se servir de la très grande capacité transgénique du virus de l'herpès simplex de type 1 (HSV-1) pour transformer le génome de ce virus en une sorte de plateforme, ou rampe de lancement, qui permettra la production in vivo d'un vecteur herpétique secondaire de type amplicon, qui portera le transgène thérapeutique à d'autres cellules, augmentant ainsi significativement le nombre de cellules qui recevront le transgène. Cette plateforme pourra également être utilisée en culture de cellules, pour améliorer la production de vecteurs amplicons non contaminés par du virus auxiliaire. De plus, les vecteurs amplicons ainsi produits, in vivo comme in vitro, ne porteront pas de séquences d'ADN bactériennes. L'élimination de l'ADN bactérien est très importante, tant pour diminuer la réponse cellulaire innée induite par la pénétration du vecteur, que pour éviter la répression de l'expression transgénique. Dans le système de vecteurs que nous nous proposons de développer, le génome d'un vecteur herpétique de type amplicon, entouré par deux sites loxP en orientation parallèle, se trouvera intégré dans le génome d'un virus herpétique recombinant. Dans les cellules infectées par le vecteur herpétique recombinant, et sous l'action de la recombinase Cre, le génome de l'amplicon sera dissocié du génome herpétique le contenant, générant ainsi deux génomes séparés dans le noyau de chaque cellule. Après dissociation, le génome du virus recombinant deviendra défectif à cause de la perte des signaux d'encapsidation (qui seront excisés avec le génome amplicon) et servira en tant que génome auxiliaire, permettant l'amplification et l'encapsidation du génome amplicon, portant le transgène, dans des particules herpétiques. Dans la mesure où chaque cellule infectée par le vecteur recombinant deviendra une usine à produire des amplicons, le nombre de cellules recevant le transgène thérapeutique porté par les amplicons devrait être considérablement élargi. Puisque le génome amplicon sera dissocié du génome HSV-1 recombinant suite à un événement de recombinaison spécifique de site, nous avons donné à ce système le nom de "Site-specific Excision-Dependent" (SED) vectors. Ce nouveau système pourra être utilisé de deux manières différentes en fonction de la localisation du gène codant pour la recombinase Cre. D'une part, il sera utilisé pour produire des stocks de vecteurs amplicons in vitro (virus SEDVITRO), auquel cas la recombinase Cre sera exprimée par les cellules dans lesquelles se fera la production d'amplicons. D'autre part, il sera utilisé pour générer des vecteurs amplicons in vivo (virus SEDVIVO), au sein de l'organisme inoculé, auquel cas la recombinase Cre sera exprimée à partir du génome du virus recombinant

  • Unveiling the role of MGMT and DAPK hypermethylation in response to anti‐EGFR agents: Molecular insights for advancing HNSCC treatment

    by Lidia Maria Rebolho Batista Arantes, Renato José Silva‐Oliveira, Ana Carolina de Carvalho, Matias Eliseo Melendez, Bruna Pereira Sorroche, Renan de Jesus Teixeira, Katiane Tostes, Edenir Inez Palmero, Rui Manuel Reis, André Lopes Carvalho

    Background: Epidermal growth factor receptor (EGFR) is frequently activated in head and neck squamous cell carcinoma (HNSCC) and serves as a valuable target for therapy. Despite the availability of the EGFR inhibitors Cetuximab, Afatinib, and Allitinib, there are limited predictive markers for their response. Understanding molecular aberrations in HNSCC could facilitate the identification of new strategies for patient clinical and biological classification, offering novel therapeutic avenues.Methods: We assessed CCNA1, DCC, MGMT, CDKN2A/p16, and DAPK methylation status in HNSCC cell lines and their association with anti‐EGFR treatment response.Results: MGMT methylation status displayed high sensitivity and specificity in distinguishing sensitive and resistant HNSCC cell lines to Afatinib (AUC = 0.955) and Allitinib (AUC = 0.935). Moreover, DAPK methylation status predicted response to Allitinib with high accuracy (AUC = 0.852), indicating their putative predictive biomarker roles.Conclusion: These findings hold promise for the development of more personalized and effective treatment approaches for HNSCC patients.


  • RAD50 Deficient in a Breast Cancer Model Predicts Sensitivity to PARP Inhibitors

    by Cíntia Regina Niederauer Ramos, Renato José Silva Oliveira, Marcela Nunes Rosa, Ariane Stéfani Pereira, Renata Barbosa Vahia de Abreu, Andre van Helvoort Lengert, Rui Manuel Reis, Viviane Aline Oliveira Silva, Edenir Inêz Palmero, Matias Eliseo Melendez

    Background: Breast and ovarian tumors with pathogenic variants in BRCA1 or BRCA2 genes are more sensitive to poly (ADP-ribose) polymerase inhibitors (PARPi) treatment than wildtype tumors. Pathogenic variants in non-BRCA1/2 homologous recombination repair genes (HRR) also concede sensitivity to PARPi treatment. RAD50 participates in the Mre11-Rad50-Nbn (MRN) complex of the HRR pathway and plays an important role in DNA repair. Objective: The objective of this study is to evaluate whether RAD50 protein deficiency modulates the PARPi response in breast cancer cell lines. Methods: T47D breast cancer cell line was modified using small interfering RNA and CRISPR/Cas9 technology, to knockout the RAD50 gene. PARPi response (niraparib, olaparib and rucaparib alone or in combination with carboplatin), in T47D and T47D-edited clones, was evaluated by cell viability, cell cycle, apoptosis and protein expression analyses. Results: Treatment with niraparib and carboplatin exerted a synergistic effect on T47D-RAD50 deficient cells and an antagonistic effect on T47D cells parental. Cell cycle analysis demonstrated an increase in the G2/M population in cells treated with niraparib or rucaparib alone or in combination with carboplatin. T47D-RAD50 deficient cells treated with rucaparib and carboplatin exhibited twofold levels in late apoptosis, also showing differences in PARP activation. All T47D RAD50 deficient clones treated with niraparib or rucaparib combined with carboplatin, or rucaparib alone showed increased levels of H2AX phosphorylation. Conclusions: T47D RAD50 deficient cells treated with PARP inhibitors alone or in combination with carboplatin showed cell cycle arrest in the G2/M phase, leading to death by apoptosis. Thus, RAD50 deficiency may be a good biomarker for predicting PARPi response.


  • miR‐99a‐5p as a biomarker for lymph node metastasis prediction in oral squamous cell carcinoma patients

    by Cristiane Pereira Vargas Cousseau, Bruna Pereira Sorroche, Renan de Jesus Teixeira, Ana Carolina de Carvalho, Matias Eliseo Melendez, Renato de Castro Capuzzo, Ana Carolina Laus, Luciane Sussuchi da Silva, Nei Soares de Menezes, André Lopes Carvalho, et al.

    Background: Metastatic lymph node involvement influences therapy decisions and serves as a prognostic indicator in oral squamous cell carcinoma (OSCC). However, many early‐stage patients with clinically negative lymph nodes exhibit no metastasis upon surgical staging. This study aimed to identify differentially expressed miRNAs capable of distinguishing pathologically positive (pN+) from negative (pN0) nodes in OSCC patients without clinical evidence of lymph node metastases (cN0).Methods: Expression levels of 798 miRNAs were assessed in tumor samples from 10 pN+ and 10 pN0 patients using the Nanostring nCounter platform. Validation was performed in an independent cohort of 15 pN+ and 24 pN0 patients through RT‐qPCR.Results: Eight miRNAs exhibited differential expression between pN0 and pN+ patients. Notably, hsa‐miR‐99a‐5p demonstrated high sensitivity and specificity in predicting patients at higher risk of positive lymph nodes.Conclusions: These findings highlight hsa‐miR‐99a‐5p as a potential biomarker for detecting lymph node metastasis in primary OSCC tumors.


  • Colorimetric Detection of SARS-CoV-2 Using Plasmonic Biosensors and Smartphones

    by Elsa M. Materón, Faustino R. Gómez, Mariana B. Almeida, Flavio M. Shimizu, Ademar Wong, Kelcilene B. R. Teodoro, Filipe S. R. Silva, Manoel J. A. Lima, Monara Kaelle S. C. Angelim, Matias E. Melendez, et al.


  • Open Access

    Whole-Exome Sequencing Identifies Pathogenic Germline Variants in Patients with Lynch-Like Syndrome

    by Wellington dos Santos, Edilene Santos de Andrade, Felipe Antonio de Oliveira Garcia, Natália Campacci, Cristina da Silva Sábato, Matias Eliseo Melendez, Rui Manuel Reis, Henrique de Campos Reis Galvão, Edenir Inez Palmero

    Lynch syndrome (LS) is the most common hereditary colorectal cancer (CRC) syndrome, characterized by germline pathogenic variants in mismatch repair (MMR)-related genes that lead to microsatellite instability. Patients who meet the clinical criteria for LS and MMR deficiency and without any identified germline pathogenic variants are frequently considered to have Lynch-like syndrome (LLS). These patients have a higher risk of CRC and extracolonic tumors, and little is known about their underlying genetic causes. We investigated the germline spectrum of LLS patients through whole-exome sequencing (WES). A total of 20 unrelated patients with MMR deficiency who met the clinical criteria for LS and had no germline variant were subjected to germline WES. Variant classification was performed according to the American College of Medical Genetics and Genomics (ACMG) criteria. Pathogenic/likely pathogenic variants were identified in 35% of patients in known cancer genes such as MUTYH and ATM. Besides this, rare and potentially pathogenic variants were identified in the DNA repair gene POLN and other cancer-related genes such as PPARG, CTC1, DCC and ALPK1. Our study demonstrates the germline mutational status of LLS patients, a population at high risk of colorectal cancer.


  • Open Access

    Efficacy of Combined Use of Everolimus and Second-Generation Pan-EGRF Inhibitors in KRAS Mutant Non-Small Cell Lung Cancer Cell Lines

    by Renato José da Silva-Oliveira, Izabela Natalia Faria Gomes, Luciane Sussuchi da Silva, André van Helvoort Lengert, Ana Carolina Laus, Matias Eliseo Melendez, Carla Carolina Munari, Fernanda de Paula Cury, Giovanna Barbarini Longato, Rui Manuel Reis

    Background: EGFR mutations are present in approximately 15–50% of non-small cell lung cancer (NSCLC), which are predictive of anti-EGFR therapies. At variance, NSCLC patients harboring KRAS mutations are resistant to those anti-EGFR approaches. Afatinib and allitinib are second-generation pan-EGFR drugs, yet no predictive biomarkers are known in the NSCLC context. In the present study, we evaluated the efficacy of pan-EGFR inhibitors in a panel of 15 lung cancer cell lines associated with the KRAS mutations phenotype. Methods: KRAS wild-type sensitive NCI-H292 cell line was further transfected with KRAS mutations (p.G12D and p.G12S). The pan-EGFR inhibitors’ activity and biologic effect of KRAS mutations were evaluated by cytotoxicity, MAPK phospho-protein array, colony formation, migration, invasion, and adhesion. In addition, in vivo chicken chorioallantoic membrane assay was performed in KRAS mutant cell lines. The gene expression profile was evaluated by NanoString. Lastly, everolimus and pan-EGFR combinations were performed to determine the combination index. Results: The GI50 score classified two cell lines treated with afatinib and seven treated with allitinib as high-sensitive phenotypes. All KRAS mutant cell lines demonstrated a resistant profile for both therapies (GI50 < 30%). The protein array of KRAS edited cells indicated a significant increase in AKT, CREB, HSP27, JNK, and, importantly, mTOR protein levels compared with KRAS wild-type cells. The colony formation, migration, invasion, adhesion, tumor perimeter, and mesenchymal phenotype were increased in the H292 KRAS mutated cells. Gene expression analysis showed 18 dysregulated genes associated with the focal adhesion-PI3K-Akt-mTOR-signaling correlated in KRAS mutant cell lines. Moreover, mTOR overexpression in KRAS mutant H292 cells was inhibited after everolimus exposure, and sensitivity to afatinib and allitinib was restored. Conclusions: Our results indicate that allitinib was more effective than afatinib in NSCLC cell lines. KRAS mutations increased aggressive behavior through upregulation of the focal adhesion-PI3K-Akt-mTOR-signaling in NSCLC cells. Significantly, everolimus restored sensibility and improved cytotoxicity of EGFR inhibitors in the KRAS mutant NSCLC cell lines.


  • Using machine learning and an electronic tongue for discriminating saliva samples from oral cavity cancer patients and healthy individuals

    by Daniel C. Braz, Mário Popolin Neto, Flavio M. Shimizu, Acelino C. Sá, Renato S. Lima, Angelo L. Gobbi, Matias E. Melendez, Lídia M.R. B. Arantes, André L. Carvalho, Fernando V. Paulovich, et al.


  • Detection of a SARS-CoV-2 sequence with genosensors using data analysis based on information visualization and machine learning techniques

    by Juliana Coatrini Soares, Andrey Coatrini Soares, Valquiria Cruz Rodrigues, Pedro Ramon Almeida Oiticica, Paulo Augusto Raymundo-Pereira, José Luiz Bott-Neto, Lorenzo A. Buscaglia, Lucas Daniel Chiba de Castro, Lucas C. Ribas, Leonardo Scabini, et al.

    First genosensor for SARS-CoV-2 where multimodal detection principles can be employed, including image analysis based on machine learning.


  • Influence of the Molecular Orientation and Ionization of Self-Assembled Monolayers in Biosensors: Application to Genosensors of Prostate Cancer Antigen 3

    by Paulo A. Raymundo-Pereira, Rafael de Oliveira Pedro, Olivia Carr, Matias E. Melendez, Angelo L. Gobbi, Maria Helena de Oliveira Piazzetta, André L. Carvalho, Rui M. Reis, Paulo B. Miranda, Osvaldo N. Oliveira